---
title: "Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688566.SH.md"
symbol: "688566.SH"
name: "Jiangsu Jibeier Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T15:43:22.810Z"
locales:
  - [en](https://longbridge.com/en/quote/688566.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688566.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688566.SH.md)
---

# Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH)

## Company Overview

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company’s products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach and gastric diseases, and other diseases. In addition, the company offers its products in tablets, capsules, and eye drops forms.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.jbepharm.com](https://www.jbepharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.58% |  |
| Net Profit YoY | 17.44% |  |
| P/B Ratio | 2.12 |  |
| Dividend Ratio | 1.97% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5274339675.77 |  |
| Revenue | 992443074.66 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 10.63% | B |
| Profit Margin | 25.65% | A |
| Gross Margin | 90.15% | A |
| Revenue YoY | 9.58% | B |
| Net Profit YoY | 17.44% | B |
| Total Assets YoY | 6.79% | B |
| Net Assets YoY | 8.54% | B |
| Cash Flow Margin | 71.77% | C |
| OCF YoY | 9.58% | B |
| Turnover | 0.38 | C |
| Gearing Ratio | 8.18% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Jibeier Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.58%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "17.44%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.97%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5274339675.77",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "992443074.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "10.63%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "25.65%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "90.15%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.58%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "17.44%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.79%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.54%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "71.77%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "9.58%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.18%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 20.82 | 50/215 | 28.86 | 25.19 | 23.78 |
| PB | 2.13 | 94/215 | 2.98 | 2.54 | 2.42 |
| PS (TTM) | 5.34 | 135/215 | 7.41 | 6.30 | 5.98 |
| Dividend Yield | 1.96% | 65/215 | 2.19% | 1.80% | 1.65% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-02-18T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 26.53 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688566.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688566.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688566.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**